

9 REFERÊNCIAS

- 1.0 Alexander, B. Sampling. *Med. Vet. Entomol.*, v.14, p. 109-122, 2001.
- 1.1 Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, Michalick MS, Williams P, Lima AO, Vieira JB, et al.. *Int J Epidemiol.* 1986 Dec;15(4):572-80.
- 1.2 Ivar J, Laguna F, Lopez-Velez R, Soriano V, Montilla P, Gonzalez-Lahoz JM. *J Infect.* 1994 May;28(3):255-9.
- 1.3 Dietze R, Barros GB, Teixeira L, Harris J, Michelson K, Falqueto A, Corey R.. *Clin Infect Dis.* 1997 Nov;25(5):1240-2.
- 1.4 Looker DL, Berens RL, Marr JJ. *Mol Biochem Parasitol.* 1983 Sep;9(1):15-28.
- 1.5 Nelso, D.L., Cox, M.M. (2005), *Lehninger, Principles of Biochemistry* 4 th ed., W. H. Freeman.
- 1.6 Girgis, N. S.; Pedersen, E. B.; *Synthesis* **1982**, 6, 480; Fu, R.; Xu, X.; Dang, Q.; Bai, X.; *J. Org. Chem.* **2005**, 70, 10810.
- 1.7 Antunes LMG, Darin JDC, Bianchi MLP. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. *Pharmacol Res* 2000; 41(4):405-11
- 1.8 Camargo SMR, Francescato HDC, Lavrador MAS, Bianchi MLP. Oral administration of sodium selenite minimizes cisplatin toxicity on proximal tubules of rats. *Biol Trace Elem Res* 2001; 83(3):251-62.
- 1.9 Bikramjit Raychaudhury, Shouvik Banerjee, Shreedhara Gupta, Ran Vir Singh, and Salil C. Datta, *Acta Tropica*, 2005, July; 1: 1-8
- 1.10 *Mem Inst Oswaldo Cruz*, Rio de Janeiro, Vol. 91(5): 625-633, Sep./Oct. 1996
- 1.11 Shi W, Schramm VL, Almo SC. Nucleoside hydrolase from *Leishmania major*. *Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-Å crystal structure.* *J Biol Chem.* 1999 Jul 23;274(30):21114-20.
- 1.12 Tanner CE. *Immunobiology of visceral leishmaniasis.* *Clin Immunol Immunopathol.* 1996 Feb;78(2):105-11. Review. No abstract available.

- 1.13** Schmidt G, Walter RD, Konigk E. *A purine nucleoside hydrolase from Trypanosoma gambiense, purification and properties.* Tropenmed Parasitol. 1975 Mar;26(1):19-26.
- 1.14** Simon L. Croft and Graham H. Coombs. *Leishmaniasis- current chemotherapy and recente advances in the search for novel drugs.* Trends in Parasitology. 2003 Nov. v.19 n°11.
- 3.0** MONTGOMERY, J. A. ; THOMSON, J.R.; SCHABEL, F.M. Cancer Res, 1959, 19, 435 – 437.
- 3.1** ACHESON, R. M, An introduction to the Chemistry of Heterocyclic Compound. 3ed – Jonh Wiley & Sons Inc, New York, 1971 , 419 – 20.
- 3.2** BROWN, D.J. ET AL. Fused Pyrmidines, Purines – Part II, Jonh Wiley & Sons Inc. New York, 1971, 1- 28.
- 3.3** KATRITZKY, A. R. ; REES, C.W. Comprehensive Heterocyclic Chemistry – the structure Reactions, Synthesis ans Uses of Heterocyclic .Compounds, Part 4a, 1ed, Pergason Press, New York, 1984, 5, 501 – 597 .
- 3.4** ALBERT, A. ; Heterocyclic Chemistry, an Introduction. Athlone Press, 1968, 251 – 253 .
- 3.5** FIELD, A. K.; DAVIES M.E.; DEWITT, C.; PERRY, H.C.; LIOU, R.; GERMESHAUSEN, J. KARKAS, J.D.; ASHTON, W.T. ; JONSTON, D.B.R.; TOLMAN, R.L. Proc. Natl. Acad. Sci. USA. 1983, 80, 4139 – 4143 .
- 3.6** CHU, C.K. ; BEACH, J.W. ,JEON, L.S.; CHOI, B.G.; COMER, F.I. ; ALVES, A.J; SCINEZI, R.F. J. Org Chem. 1991, 56, 6503 – 6505 .
- 3.17** BOLON, P.J.; WANG, P.Y.; CHU, C.K.; GOSSELIN, G. ; BOUDOUM V. ; PIERA, C. ; MATHE, C. ; IMBACH, J.L.; FARAJ, A. ; et al. Biorg.Med.Chem.Lett. 1996, 6(14) 1657 – 1662, Chem Abst. 1996, 125, 211862v .
- 3.18** LEONARD, N.J.;FUJII, T.J. Am. Soc., 1963, 3719.
- 3.19** MONTGOMERY, J.;A.; THOMAS, H.J.J.Org, 1996, 30, 3235-3236.
- 3.20** TSUKARA, M.; HIROSAWA, T.; KISHINE, S.; J. Plant. Physiol. 1996, 149(1/2) 157 – 162 .
- 3.21** ZUNIGA – AGUILAR, J.J.; LOPES, I. ; GOMES, A.; VASQUEZ – RAMOS, J.M. Seed Sic.Res. 1995, 5(4), 219-226, Chem. Abst., 1996, 124, 198236b.
- 3.22** WANG, X. ; ZHAO, Q. ; LIU, C. ; WANG, D. ; XI, Y. Huaxi Yaoxue Zazhi. 1997, 12(1), 1 – 3, Chem. Abst., 1997, 126, 287631k.

- 3.23** KONG, S.L.; MARZIAH, M.; NORLELA, K. ; Proc. Malasys. Biochem. Soc. Conf. 1994, 19 th, 116-117, Chem Abs., 1994, 124, 226797f.
- 3.25** HISHINUMA, M. ; MAMOTO, K. OGUMA, T. ; MORITANI, N. Patente Japan Kokai 7.751.394, 1977, Chem. Abst. 1977, 87: 135309g.
- 3.26** HULL, R.J. Chem. Soc, 1958, 2746-2791.
- 3.27** NOELL, W.; ROBINS, R.K. J. Am Chem Soc, 1959, 81, 5997-6007.
- 3.28** SENG, W.H.; HUESHI, Y.S.; WU, W.L. Husue Pao, 1977, 9(1), 112, Chem Abst, 1978, 121111n
- 3.29** MIKSTAIS, U. ; Patente S.U. 857.137, 1981, Chem Abst., 1982, 98, 6483p.
- 4.0** ROSENBERG, B.; VANCAMP, L.; TROSKO, J.F.; MANSOUR, V.H. Nature, London, [s.n.], 1969, v.222, p. 385-6.
- 4.1** KRAKOFF, I.H. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy: Clinical Applications of Platinum Complexes; Nicoline, M., ED. Boston: Martinus N. Publishing, 1988, p.351.
- 4.2** KRAKOFF, I.H. Cancer Treat. Resp., 63, 1623, 1979.
- 4.3** Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55(15): 2303-15.
- 4.4** Jones TW, Chopra S, Kaufman JS, Flamenbaun W, Trump B. Cis-diamminedichloroplatinum(II) induced renal failure in the rat. Correlation of structural and functional alterations. Lab Invest 1985; 52(2):363-74.
- 4.5** Choie DD, Longnecker DS, Del Campo A. Acute and chronic cisplatin nephropathy in rats. Lab Invest 1981; 44(5):397-402.
- 4.6** Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997;23(3):140-3.
- 4.7** Volland, J.F. et al. J. Med. Chemistry, 1987, v.30, p.716-719.
- 4.8** McKEAGE, M. J. Brit J. Cancer.1991, 64, 788 (procurar editor).
- 4.9** NAVARRO- RANNINGER, C; LOPEZ-SOLERA, I; PEREZ, J M.; MASAGUER, J. R.; ALONSO, C. Appl. Organometal Chem., 1993, 7, 57.
- 4.10** CLETON, F.J.. Oxford Textbook of Oncology Vol 1, ed. Peckham, M., Pinedo, H.M., Veronesi, H.: Oxford University Press, 1995. p. 445-453.
- 4.11** MACHADO, A. E. D.; Quim. Nova, 2000, 23, 237.
- 4.12** OLIVEIRA, R.B.; ALVES, R.J.; Quim. Nova, 2000, 25, 976.
- 4.13** Douglas X. West and Anthony E. liberta Coordination Chemistry Reviews, 1993, 123, 49-71.


- 4.14** W. C. Kaska, C. Carrans, J. Michalowski, J. Jackson and W. Levinson, *Bioinorg. Chem.* 1978, 8,225.
- 4.15** D.L. Klayman, J. E. Bartosevich, T.S. Griffith, C.J. Mason and J.P. Scovill, *J. Med. Chem.* 1979, 22, 885. (b) *J. Med. Chem.* 1979, 22,1367.
- 4.16** In press, Tiekink, E.R.T. Critical Rew. In *Oncology/ Hematology* 2002. (b) smith, K.A; Raionone, S. e outros *Metal-Based Drugs* 1998, 5: 295-304.
- 4.17** Rosenberg, B.; Van Camp, L.; Krigas, T. *Nature* 1965, 205, 698.
- 4.18** Rosenberg, B.; Van Camp, L.; Trosko, J. E.; Mansour, V. H. *Mature* 1969, 222, 385.
- 4.19** SALMONN, S.E. *Farmacologia Básicas & Clínicas*, Katzung, B.G., ed.; Rio de Janeiro: Guanabara Koogan S.A, 1998, p. 629-655.
- 4.20** HAHN, W.C.; WEINBERG, R.A.; *Nat. Rev. Cancer*, 2002, 2, 331.
- 4.21** TAKEDA, M.; KOIDE, H.; JUNG, K.Y.; ENDOU, H. *Intranephron Distribution of Glycine-Amidinotransferase Activity in Rats. Ren. Physiol. Bioch.*, 1992, V.15(3-4), p.113-118.
- 4.22** DU VIGNEAUD, V.; COHN, M.; CHLANDLER, J. P.; SCHENECK, J. R.; SIMMONDS, S. J. *Biol. Chem.*, 1941,140, 625.
- 4.23** FUJIOKA, M.; TAKATA, Y.; GOMI, T; *Arch. Biochem. Biophys.*, 1991, 285, 181-186.
- 4.24** MUDD, S. H.; POOLE, J. R. *Metalbol. Clin. Exp.*, 24, 721-735, 1975.
- 4.25** STOCKLER, S.; HANEFELD, F.; FRAHM, J. *The Lancet*, 1996, vol. 348, p. 789-790.
- 4.26** FELCMAN, J.; MIRANDA, J. L. . Guanidino-Carboxylate Interactions In Mixed Complexes Of Copper(II) And Zin(II) Of Biological Importance.. In: *Fourth European Biological Inorganic Chemistry Conference*, 1998. *Book of Abstracts*. Sevilha, Espanha. v. 1. p. 120-120.
- 4.27** FELCMAN, J. ; MIRANDA, J. L. *Ligand-ligand Interactions of Biological Importance in Copper(II) Mixed Complexes of Guanidinoacetic Acid*. In: *37th IUPAC Congress*, 1999, Berlin. *Abstracts*. Berlin :Sociedade Alemã de Química, 1999. v. 2. p. 567-567.FELCMAN, J. ; MIRANDA, J. L. . Complexos ternários de Co(II) e ácido guanidoacético de importância biológica. In: *23a. Reunião Anual da Sociedade Brasileira de Química*, 2000, Poços de Caldas. *Livro de Resumos da 23a. Reunião ANual da SBQ*. São Paulo : Sociedade Brasileira de Química, 2000. v. 1. p. QI022-QI022.

- 4.29** MIRANDA, J. L.; FELCMAN, J. ; SOTO, C. T. . Study Of Cr(III), Zn(II) And Ni(II) Guanidinoacetic Complexes. In: IX Brazilian Meeting on Inorganic Chemistry, 1998. Abstracts. Angra dos Reis, RJ, Brasil. v. 1. p. 169-170.
- 4.30** FELCMAN, J. ; MIRANDA, J. L. . Um modelo de como o ácido guanidoacético se liga a enzima guanidinometiltransferase. In: 24a. Reunião Anual da SBQ, 2001, poços de Caldas. Livro de Resumos da 24a reunião Anual da SBQ. São Paulo : Sociedade Brasileira de Química, 2001. v. 1. p. QI061-QI061.
- 4.31** SZYFMAN, N. W. ; FELCMAN, J. . Estudo de Complexos Mistos do íon Vanadila e Ácidos guanidoacético, Aspartico, Glutâmico e Glicina. In: 25a. Reunião Anual da SBQ, 2002, Poços de Caldas. Livro de Resumos da 25a. Reunião Anual da SBQ, 2002. v. 1. p. QI066-QI066.
- 4.33** MIRANDA, J. L.; FELCMAN, J. ; WARDELL, J. L. ; SKAKLE, J. . Synthesis and X-Ray Analysis of the First Dimeric Copper (II) Complex of Guanidino Acetic Acid. In: XI Brazilian Meeting on Inorganic Chemistry, 2002, Ouro Preto. Livro de resumos, 2002. v. 1. p. 125-125.
- 4.34** VERSIANE, O. ; RODRIGUES, B. L. ; MIRANDA, J. L. ; FELCMAN, J. A Methylenic Group Binds Guanidinoacetic Acid to Glycine and Serine in Two Novel Copper (II) Complexes: Synthesis, X-Ray-Structure and Spectroscopic Characterization.. In: 12th International Conference on Biological Inorganic Chemistry, 2005, Ann Harbour. CD, 2005.
- 4.35** SALMONN, S.E. Farmacologia Básicas & Clínicas, Katzung, B.G., ed.; Rio de Janeiro: Guanabara Koogan S.A, 1998, p. 629-655.
- 4.36** HAHN, W.C.; WEINBERG, R.A.; Nat. Rev. Cancer, 2002, 2, 331.
- 5.0** Vogel. A.1989. *Textbook of quantitative chemical analysis*, 5th ed.New York: Longman and John Wiley and Sons. 387.
- 6.0** Figueroa-Villar JD FigueroaVillar JD Villar JDF Figueroa D ; MOTTA, M. A. . Synthesis of 6-Alkyl- and Arylamino-9-(tetrahydro-2-pyranyl)purines via 6-Methylsulfonylpyrimidine.. Nucleosides, Nucleotides & Nucleic Acids, USA, v. 19, n. 5&6, p. 1005-1015, 2000.
- 6.1** SILVERSTEIN, R.M.; BASSLER, G.C.; MORRIL, T.C. Spectrometric Identification of Organic Compounds, 5 ed., John Wiley & Sons, Inc., New York, 1991.
- 6.2** Ferreira Victor; Cunha Anna; Paixão Menezes; Cecília Maria; Cloreto isocianúrico: Aspectos Gerais em Síntese, Química Nova, Vol 29, Nr 3, 520-527, 2006.


ANEXO A

Análise termogravimétrica obtida no equipamento Perkin- Elmer TGA7-
Scanning Rate: 5.0 C/min.


1 A - Composto I




2 A - Composto II




3 A – Composto III




4 A – Composto IV




5 A – Complexo 1




6 A – Complexo 2



7 A – Complexo 3




8 A – Complexo 4



ANEXO B


Espectro de infravermelho obtidos com Espectrometro de Infravermelho Perkin Elmer FT-IR 2000. Para a região de 4000 a 370 cm^{-1} foram utilizadas pastilhas de KBr, e para região de 570 a 30 cm^{-1} , pastilhas de polietileno.

1 B –Cisplatina




Espectro de IR obtida com pastilha de Kr

2 B –Cisplatina




Espectro de IR obtida com pastilha de polietileno

3 B - 6-Mercaptopurina




Espectro de IR obtida com pastilha de KBr

4 B - 6-Metilsulfonilpurina




Espectro de IR obtida com pastilha de KBr

5 B - Composto I




Espectro de IR obtida com pastilha de KBr.

6 B - Composto I




Espectro de IR obtida com pastilha de polietileno

7 B - Composto II




Espectro de IR obtida com pastilha de KBr

8 B - Composto II




Espectro de IR obtida com pastilha de poliestileno.

9 B – Composto III




Espectro de IR obtida com pastilha de Kr

10 B – Composto III




Espectro de IR obtida com pastilha de polietileno

11 B – Composto IV




Espectro de IR obtida com pastilha de Kr

12 B – Composto IV




Espectro de IR obtida com pastilha de polietileno

13 B – Complexo 1




Espectro de IR obtida com pastilha de KBr

14 B – Complexo 1




Espectro de IR obtida com pastilha de polietileno .

15 B – Complexo 2




Espectro de IR obtida com pastilha de KBr

16 B – Complexo 2




Espectro de IR obtida com pastilha de polietileno

17 B – Complexo 2




Espectro de IR obtida com pastilha de KBr.

18 B – Complexo 3




Espectro de IR obtida com pastilha de polietileno

19 B – Complexo 4



Espectro de IR obtida com pastilha de KBr

20 B – Complexo 4




Espectro de IR obtida com pastilha de polietileno

ANEXO C


Os espectros de massa apresentados neste trabalho foram obtidos no espectrômetro de massa Bruker Biflex III do Laboratório Van de Graaff do Departamento de Física da PUC-Rio.

1 C – Composto I




Espetro de massas do composto 1

2 C – Composto II




Espectro de massas do composto 2

3 C – Composto III




Espectro de massas do composto 3

4 C – Composto IV




Espectro de massas do composto 4.

5 C – Complexo 1




Espectro de massas do complexo 1

6 C – Complexo 2




Espectro de massas do complexo 2.

7 C – Complexo 3



Espectro de massas do complexo 3.

8 C – Complexo 4




Espectro de massas do composto


ANEXO D

Todos os composroa foram analisados no espectrometro de Ressonância Magnética nuclear (RMN) – Varian, Unity 300 (IME, RJ).

1 D – 6-metilmercaptapurina


RMN- ^1H





RMN ^{13}C 

2 D – 6-metilmesulfonilpurina

RMN-¹H




RMN-¹³C


RMN- ^1H 

RMN-¹³C


3 D-Composto II


RMN-¹H




RMN- ^{13}C 

4 D- Composto III

RMN-¹H

RMN-¹³C

5 D- Composto IV

RMN-¹H

RMN-¹³C